Institutional Moves in Major U.S. Equities

Recent regulatory filings show sizeable third-quarter portfolio adjustments by major institutional investors across pharmaceuticals, life sciences and technology stocks, affecting companies including Pfizer (PFE), Adobe (ADBE), Agilent Technologies, Bio-Techne, Arista Networks and Regeneron Pharmaceuticals (REGN).

Mackenzie Financial Corp, Franklin Resources Inc. and other large managers either expanded or trimmed holdings, while additional hedge funds and wealth managers made incremental changes, reinforcing high institutional ownership levels in these names.

Mackenzie Financial Corp reduced its stake in Bio-Techne Corp by 2.3% in the third quarter, selling 59,511 shares and ending the period with 2,559,590 shares, or about 1.64% of the company, valued at $142.39 million.

Over the same quarter, Mackenzie lifted its position in Agilent Technologies by 52.8%, purchasing an additional 324,461 shares to hold 938,670 shares, representing 0.33% of Agilent and valued at $120.48 million.

Mackenzie also increased its Pfizer(PFE) holdings by 119.6% in the third quarter, adding 1,691,773 shares to reach 3,106,644 shares, worth $79.16 million and accounting for about 0.05% of the biopharmaceutical company.

Franklin Resources Inc. expanded its Pfizer stake by 47.8% in the third quarter, acquiring 8,108,887 additional shares to own 25,070,148 shares valued at $638.79 million, or roughly 0.44% of the company.

Franklin also increased its Adobe position by 6.1%, buying 117,390 shares to hold 2,056,408 shares valued at $725.40 million, equivalent to about 0.49% of the software company.

Other large investors, including Vanguard Group, Geode Capital, Fisher Asset Management, and Legal & General, reported incremental additions to Pfizer and Adobe, contributing to institutional ownership of 68.36% in Pfizer and 81.79% in Adobe.

Bio-Techne reported quarterly earnings per share of $0.46, above the $0.43 consensus, on revenue of $295.88 million, slightly ahead of expectations but down 0.4% year over year. Analysts expect full-year EPS of 1.67.

Regeneron Pharmaceuticals(REGN) posted EPS of $11.44, beating forecasts of $10.74, on revenue of $3.88 billion, up 2.5% from a year earlier. The company’s full-year EPS is projected at 35.92.

Pfizer reported EPS of $0.66, topping the $0.57 consensus, with revenue of $17.56 billion, down 1.2% year over year. Analysts on average see Pfizer earning 2.95 per share this fiscal year.

Bio-Techne paid a $0.08 quarterly dividend, or $0.32 annualized, for a 0.6% yield, while Regeneron increased its quarterly dividend to $0.94, or $3.76 annualized, for a 0.5% yield. Pfizer paid a $0.43 quarterly dividend, equal to $1.72 annually, yielding 6.3%.

As of the latest quotes, Bio-Techne traded at $53.62, near the lower half of its 12‑month range, with a market capitalization of $8.39 billion, a P/E ratio of 105.14 and a debt-to-equity ratio of 0.13.

Agilent shares opened at $115.44, giving a $32.62 billion market cap, a P/E of 25.48 and a debt-to-equity ratio of 0.44. The company issued FY 2026 EPS guidance of 5.90 to 6.04 and second-quarter 2026 EPS guidance of 1.39 to 1.42.

Pfizer’s stock opened at $27.30, close to its 52‑week high of $27.94, with a market cap of $155.24 billion and a P/E of 20.07, while Regeneron traded at $774.66, near its one-year high of $821.11, at a P/E of 18.64 and debt-to-equity of 0.09.

Adobe shares opened at $273.70, below their 12‑month high of $443.90, with a $112.35 billion market value, P/E of 16.38 and debt-to-equity of 0.53. Arista Networks traded at $138.33, with a $173.81 billion market cap and a P/E of 50.12.

In Arista Networks, insiders sold 196,237 shares worth $25.87 million over the last three months, including transactions by directors Charles H. Giancarlo and Yvonne Wassenaar, leaving insiders with 3.39% of the stock.

Regeneron insiders sold 5,274 shares valued at $4.14 million in the past 90 days, including sales by SVP Jason Pitofsky and Director Bonnie L. Bassler, and corporate insiders now hold 7.02% of the company.

Adobe reported an insider sale by CFO Daniel Durn, who sold 1,646 shares at an average of $294.85, reducing his direct holdings to 41,995 shares; overall, 0.20% of Adobe stock is held by corporate insiders.

Analyst coverage across these companies is generally positive: Bio-Techne, Agilent, Arista Networks and Regeneron all carry consensus "Moderate Buy" ratings, while Pfizer and Adobe hold average "Hold" ratings, with updated price targets reflecting recent results and outlooks.